Reviewed by Michael Gill, B. Sc.
Image of Duke University Health Systems in Durham, United States.
Phase-Based Progress Estimates
1
Effectiveness
1
Safety

EES Onfor Contusions

18+
All Sexes
The purpose of this feasibility study is to compare the impact of Spinal cord stimulation [SCS] for Spinal Cord Injury (SCI) pain and rehabilitation. SCS, also known as Epidural Electrical Stimulation (EES), will be utilized along with conventional medical management (CMM) or CMM alone. Participation in this research study is expected to last approximately 12 months. All subjects will be evaluated and proceed with implantation of two SCS devices- one tailored based on the individual's SCI for the treatment of neuropathic pain of trunk and limb and a second near the bottom of the spinal cord (conus region) to study the impact on motor, sensory, bowel/bladder outcomes. All patients will also continue receiving CMM, such as medications and physical therapy. Participating subjects will be randomly assigned to one of two treatment groups: Placebo arm: SCS OFF + CMM. Under the direction of the study physician, the patient may receive a variety of treatments, such as medications and various forms of rehabilitation. Treatment arm: SCS ON + CMM. The study treatment Spinal Cord Stimulation [SCS]: the study physician will perform a trial procedure to see if the study procedure works for the patient and may implant a permanent device if it is successful. There is a temporary trial procedure, or a "test drive," which usually lasts 5-7 days. If this is successful, patients will discuss a more permanent implant. This study involves the concurrent placement of two SCS devices (one focused on pain and the second for rehabilitation). For three months, treatment group subjects will have the SCS turned on and will have rehabilitation as part of their CMM. Participants in the placebo arm will have their SCS remain off and will undergo CMM with rehabilitation therapy similar to the treatment group. Neither the subjects nor the treatment team will know which patients are in the treatment or placebo arm. At the end of three months, the study group will be revealed and the placebo group subjects will be allowed to crossover and have their SCS turned on. Rehabilitation visits may be remote and the study duration is approximately 12 months. There may be additional blood tests and clinical exams to collect data on the effectiveness of the therapy. Data at follow-up visits will be compared to the subjects' baseline data and that of the control group at the respective visits.
Recruiting
Online Trial
Duke University Health SystemsShivanand Lad, MD, PhD
23 Scs Clinical Trials Near Me
Top Hospitals for Scs Clinical Trials
Image of Goodman Campbell Brain and Spine in Indiana.
Goodman Campbell Brain and Spine
Carmel
3Active Trials
0All Time Trials for Scs
2018First Scs Trial
Image of Hope Biosciences Stem Cell Research Foundation in Texas.
Hope Biosciences Stem Cell Research Foundation
Sugar Land
2Active Trials
0All Time Trials for Scs
2021First Scs Trial
Top Cities for Scs Clinical Trials
Image of Winston-Salem in North Carolina.
Winston-Salem
3Active Trials
The Center for Clinical ResearchTop Active Site
Image of Carmel in Indiana.
Carmel
3Active Trials
Goodman Campbell Brain and SpineTop Active Site
Top Treatments for Scs Clinical Trials
Treatment Name
Active Scs Clinical Trials
All Time Trials for Scs
First Recorded Scs Trial
Spinal Cord Stimulation
2
2
2018
Transcutaneous spinal cord stimulation
1
1
2022
VIA Disc NP
1
1
2021
HB-adMSCs
1
1
2021
Interferon gamma-primed mesenchymal stromal cells (MSCs)
1
1
2022

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 30th, 2021

Last Reviewed: November 14th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 O'Connell NE, Ferraro MC, Gibson W, Rice AS, Vase L, Coyle D, Eccleston C. Implanted spinal neuromodulation interventions for chronic pain in adults. Cochrane Database Syst Rev. 2021 Dec 2;12:CD013756. doi: 10.1002/14651858.CD013756.pub2. Review. https://pubmed.ncbi.nlm.nih.gov/348544732 Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015 Aug 29;386(9996):896-912. doi: 10.1016/S0140-6736(14)61393-3. Epub 2015 Apr 19. Review. https://pubmed.ncbi.nlm.nih.gov/259040813 Ra JC, Shin IS, Kim SH, Kang SK, Kang BC, Lee HY, Kim YJ, Jo JY, Yoon EJ, Choi HJ, Kwon E. Safety of intravenous infusion of human adipose tissue-derived mesenchymal stem cells in animals and humans. Stem Cells Dev. 2011 Aug;20(8):1297-308. doi: 10.1089/scd.2010.0466. Epub 2011 Mar 17. https://pubmed.ncbi.nlm.nih.gov/213032664 Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. CMAJ. 2005 Feb 1;172(3):367-79. Review. https://pubmed.ncbi.nlm.nih.gov/156841215 Musial-Wysocka A, Kot M, Majka M. The Pros and Cons of Mesenchymal Stem Cell-Based Therapies. Cell Transplant. 2019 Jul;28(7):801-812. doi: 10.1177/0963689719837897. Epub 2019 Apr 24. https://pubmed.ncbi.nlm.nih.gov/310186696 Marsden CD. Problems with long-term levodopa therapy for Parkinson's disease. Clin Neuropharmacol. 1994;17 Suppl 2:S32-44. Review. https://pubmed.ncbi.nlm.nih.gov/93581937 Armstrong MJ, Okun MS. Diagnosis and Treatment of Parkinson Disease: A Review. JAMA. 2020 Feb 11;323(6):548-560. doi: 10.1001/jama.2019.22360. Review. https://pubmed.ncbi.nlm.nih.gov/320449478 Armstrong MJ, Okun MS. Diagnosis and Treatment of Parkinson Disease: A Review. JAMA. 2020 Feb 11;323(6):548-560. doi: 10.1001/jama.2019.22360. https://pubmed.ncbi.nlm.nih.gov/320449479 Musiał-Wysocka A, Kot M, Majka M. The Pros and Cons of Mesenchymal Stem Cell-Based Therapies. Cell Transplant. 2019 Jul;28(7):801-812. doi: 10.1177/0963689719837897. Epub 2019 Apr 24. Review. https://pubmed.ncbi.nlm.nih.gov/3101866910 Dimarino AM, Caplan AI, Bonfield TL. Mesenchymal stem cells in tissue repair. Front Immunol. 2013 Sep 4;4:201. doi: 10.3389/fimmu.2013.00201. Review. https://pubmed.ncbi.nlm.nih.gov/24027567